Mapping the value for money of precision medicine: a systematic literature review and meta-analysis.
dc.contributor.author | Chen, Wenjia | |
dc.contributor.author | Wong, Nigel Chong Boon | |
dc.contributor.author | Wang, Yi | |
dc.contributor.author | Zemlyanska, Yaroslava | |
dc.contributor.author | Butani, Dimple | |
dc.contributor.author | Virabhak, Suchin | |
dc.contributor.author | Matchar, David Bruce | |
dc.contributor.author | Prapinvanich, Thittaya | |
dc.contributor.author | Teerawattananon, Yot | |
dc.date.accessioned | 2024-03-25T08:16:06Z | |
dc.date.available | 2024-03-25T08:16:06Z | |
dc.date.issued | 2023-01 | |
dc.description.abstract | ObjectiveThis study aimed to quantify heterogeneity in the value for money of precision medicine (PM) by application types across contexts and conditions and to quantify sources of heterogeneity to areas of particular promises or concerns as the field of PM moves forward.MethodsA systemic search was performed in Embase, Medline, EconLit, and CRD databases for studies published between 2011 and 2021 on cost-effectiveness analysis (CEA) of PM interventions. Based on a willingness-to-pay threshold of one-time GDP per capita of each study country, the net monetary benefit (NMB) of PM was pooled using random-effects meta-analyses. Sources of heterogeneity and study biases were examined using random-effects meta-regressions, jackknife sensitivity analysis, and the biases in economic studies checklist.ResultsAmong the 275 unique CEAs of PM, publicly sponsored studies found neither genetic testing nor gene therapy cost-effective in general, which was contradictory to studies funded by commercial entities and early stage evaluations. Evidence of PM being cost-effective was concentrated in a genetic test for screening, diagnosis, or as companion diagnostics (pooled NMBs, $48,152, $8,869, $5,693, p < 0.001), in the form of multigene panel testing (pooled NMBs = $31,026, p < 0.001), which only applied to a few disease areas such as cancer and high-income countries. Incremental effectiveness was an essential value driver for varied genetic tests but not gene therapy.ConclusionPrecision medicine's value for money across application types and contexts was difficult to conclude from published studies, which might be subject to systematic bias. The conducting and reporting of CEA of PM should be locally based and standardized for meaningful comparisons. | |
dc.identifier.issn | 2296-2565 | |
dc.identifier.issn | 2296-2565 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Frontiers Media SA | |
dc.relation.ispartof | Frontiers in public health | |
dc.relation.isversionof | 10.3389/fpubh.2023.1151504 | |
dc.rights.uri | ||
dc.subject | Cost-Benefit Analysis | |
dc.subject | Precision Medicine | |
dc.title | Mapping the value for money of precision medicine: a systematic literature review and meta-analysis. | |
dc.type | Journal article | |
duke.contributor.orcid | Matchar, David Bruce|0000-0003-3020-2108 | |
pubs.begin-page | 1151504 | |
pubs.organisational-group | Duke | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | Medicine, General Internal Medicine | |
pubs.organisational-group | University Initiatives & Academic Support Units | |
pubs.organisational-group | University Institutes and Centers | |
pubs.organisational-group | Duke Global Health Institute | |
pubs.publication-status | Published | |
pubs.volume | 11 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Mapping the value for money of precision medicine a systematic literature review and meta-analysis.pdf
- Size:
- 1.73 MB
- Format:
- Adobe Portable Document Format